398 related articles for article (PubMed ID: 33084382)
1. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
2. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA
AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
4. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
7. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT,
Yoo J; Lee JM; Joo I; Lee DH; Yoon JH; Yu MH; Jang JY; Lee SH
Cancer Imaging; 2023 May; 23(1):49. PubMed ID: 37217958
[TBL] [Abstract][Full Text] [Related]
8. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.
Lee W; Oh M; Kim JS; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Yoo C; Kim KP; Jeong JH; Chang HM; Ryoo BY; Park SY; Kim SC
Br J Surg; 2021 Dec; 109(1):61-70. PubMed ID: 34378010
[TBL] [Abstract][Full Text] [Related]
10. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
11. Prediction of residual tumor and overall survival after first-line surgery in patients with pancreatic ductal adenocarcinoma using preoperative magnetic resonance imaging findings.
Bae JS; Kim JH; Kang HJ; Han JK
Acta Radiol; 2022 Apr; 63(4):435-446. PubMed ID: 33682455
[TBL] [Abstract][Full Text] [Related]
12. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?
Denecke T; Rau B; Hoffmann KT; Hildebrandt B; Ruf J; Gutberlet M; Hünerbein M; Felix R; Wust P; Amthauer H
Eur Radiol; 2005 Aug; 15(8):1658-66. PubMed ID: 15806369
[TBL] [Abstract][Full Text] [Related]
15. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Skaltsa K; Domènech B; Lomeña F; Pons F
Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):291-8. PubMed ID: 22695339
[TBL] [Abstract][Full Text] [Related]
16. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
18. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
Dunet V; Halkic N; Sempoux C; Demartines N; Montemurro M; Prior JO; Schmidt S
Eur Radiol; 2021 Feb; 31(2):992-1001. PubMed ID: 32851447
[TBL] [Abstract][Full Text] [Related]
19. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
20. Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer.
Dalah E; Moraru I; Paulson E; Erickson B; Li XA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):633-40. PubMed ID: 24755533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
